Navigation Links
Clermont Pharmaceuticals Reports Positive Phase III Results for Drug to Treat Glaucoma

TAMPA, Fla., Sept. 26, 2011 /PRNewswire/ -- Clermont Pharmaceuticals, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today positive results from a phase III trial of non-preserved latanoprost In the study, non-preserved latanoprost was compared to Xalatan® (latanoprost ophthalmic solution) 0.005%, in subjects diagnosed with open-angle glaucoma.  Non-preserved latanoprost achieved the primary efficacy endpoint of non-inferiority to Xalatan.  In addition, non-preserved latanoprost was better tolerated than Xalatan, with statistically fewer ocular symptoms on instillation and significantly fewer subjects with conjunctival hyperemia.  Xalatan is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension; it was approved by the US Food and Drug Administration for use in 1996.  Xalatan is the registered trademark of Pfizer, Inc. 

Clermont obtained the US rights to non-preserved latanoprost from Laboratoires Thea S.A.S, an ophthalmic pharmaceutical company based in France.  Laboratoires Thea recently filed an application for European marketing authorization with the EMEA. 

Based on these positive results, Clermont intends to file a New Drug Application with the US FDA in the fourth quarter of 2011.  Clermont plans to begin discussions with potential marketing partners in the near future.   

About Open-Angle Glaucoma

Open-angle glaucoma is the most common type of glaucoma and the leading cause of blindness among adults in the US – mostly because it can progress gradually and go unnoticed for years.  An increase in eye pressure occurs slowly over time.  This pressure pushes on the optic nerve and the retina at the back of the eye.  The cause of open-angle glaucoma is unknown, but it tends to be hereditary, with people of African descent at particularly high risk. 

About Clermont Pharmaceuticals

Clermont Pharmaceuticals, Inc. is a privately held Florida based ophthalmic pharmaceutical company focused on the development of new medicines for the treatment glaucoma. 

About Laboratoires Thea

Laboratoires Thea was founded in 1994 and is managed by Henri and Jean-Frederic Chibret. Laboratoires Thea is a 350 MUSD ophthalmic pharmaceutical company and is the leading independent ophthalmic group in Europe and is committed to the development and marketing of innovative ophthalmic drugs, medical devices, and nutraceuticals.

SOURCE Clermont Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Announces Efficacy and Safety of EXPAREL™ Highlighted at "Hot Topics in Plastic Surgery" Panel at the 2011 Annual Meeting of the American Society of Plastic Surgeons
2. Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
3. Zacks Industry Outlook Highlights: Vertex Pharma, AstraZeneca, Abbott Labs, Allergan and Onyx Pharmaceuticals
4. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
5. Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
6. Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine
7. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
8. Isis Pharmaceuticals and BioMed Realty Trust Celebrate Grand Opening of New R&D Facility in Carlsbad, California
9. CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001
10. Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing
11. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
Post Your Comments:
(Date:11/27/2015)... DUBLIN , Nov. 27, 2015 Research ... of the "Global Intrauterine Devices Market 2015-2019" ... --> In this report, the author ... intrauterine devices market for 2015-2019. To calculate the market ... of following type of products: Hormonal IUDs and copper ...
(Date:11/26/2015)... november 2015 AAIPharma Services Corp./Cambridge ... investering aan van ten minste $15,8 miljoen ... het mondiale hoofdkantoor in Wilmington, ... in extra kantoorruimte en extra capaciteit voor ... behoeften van de farmaceutische en biotechnologische markten. ...
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... progress through sharing, the 2016 Building Better Radiology Marketing Programs meeting ... begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, ... interesting show that delves into an array of issues that are presently affecting Americans. ... from open dialogue, this show is changing the subjects consumers focus on, one episode ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... an innovative online platform for mental health and wellness consultation, has collaborated with ... partnership will bridge the knowledge gap experienced by parents and bring advice from ...
(Date:11/27/2015)... IL (PRWEB) , ... November 27, 2015 , ... ... of the largest, most successful and prominent nonprofit healthcare organizations in the country. ... governance involvement with various organizations, and helped advance the healthcare industry as a ...
(Date:11/27/2015)... Francisco, California (PRWEB) , ... November 27, 2015 , ... ... Janis Joplin Ann Arbor Michigan boxing style concert posters. This is one of Joplin's ... at the Canterbury House at the University of Michigan in Ann Arbor. The According ...
Breaking Medicine News(10 mins):